Optimal vasopressor sequencing in septic shock with concurrent RV failure?

54M admitted to MICU with septic shock secondary to community-acquired pneumonia. Bedside echo showing acute RV dilation with TAPSE 12mm, D-shaped septum, and McConnell's sign.

Currently on norepinephrine 0.4 mcg/kg/min with MAP 58. Lactate trending up from 4.2 → 6.8 mmol/L over 2 hours.

My concerns:

NE may worsen pulmonary vascular resistance → RV afterload
Adding vasopressin early vs escalating NE first
Role of dobutamine vs milrinone for RV support in this context
When to consider inhaled epoprostenol

What is your approach to vasopressor/inotrope sequencing when septic shock and acute RV failure coexist?

Great case. This is a common but high-stakes clinical scenario. Here is my stepwise approach:

1. Vasopressin as early add-on (not NE escalation)

In RV failure, norepinephrine at higher doses will disproportionately increase PVR. I add vasopressin 0.03 to 0.04 U/min early. It is a systemic vasoconstrictor that has a neutral to mildly vasodilatory effect on the pulmonary vasculature via V1 receptors.

2. Targeted RV inotropy

Once MAP is supported (>65), I add low-dose dobutamine (2.5 to 5 mcg/kg/min) for RV contractility. I avoid milrinone here. Its systemic vasodilation can be catastrophic in concurrent distributive shock.

3. Inhaled epoprostenol

If RV function does not improve on echo reassessment (repeat TAPSE, RV FAC) within 2 to 4 hours, I start inhaled epoprostenol 20 to 50 ng/kg/min. This selectively reduces PVR without systemic hypotension.

Key monitoring targets:

CVP trend (not absolute value)
Serial bedside echo q4-6h
Mixed venous O2 sat via PA catheter if available
Lactate clearance > 10%/2h

I largely agree with Dr. Iyer's approach but want to emphasize one nuance. The SOAP-II trial showed that dopamine increased arrhythmia risk compared to NE, and I have seen colleagues reflexively reach for dopamine when NE "isn't working." In the setting of RV failure, dopamine is particularly problematic because its chronotropic effect increases myocardial oxygen demand in an already compromised RV.

My threshold for adding vasopressin is lower than most: I add it at NE 0.2 mcg/kg/min rather than waiting for 0.4, especially when I see RV dysfunction on echo. The VASST trial subgroup data suggested a mortality benefit for vasopressin in patients with less severe shock, which supports this early approach.

For the dobutamine question: start low (2 mcg/kg/min) and titrate by TAPSE improvement, not by cardiac index alone.

From an anesthesiology/hemodynamics perspective, I would add that phenylephrine should be avoided at all costs in this setting. Pure alpha-1 agonism without beta-1 support will increase RV afterload without improving RV contractility.

Regarding the dobutamine vs milrinone debate: in the OR setting I sometimes use milrinone for RV failure, but that is with the ability to rapidly fluid-load and add phenylephrine if needed. In septic shock, where you already have distributive pathology, milrinone's vasodilatory properties make it a poor choice. Dobutamine is the safer option.

One additional consideration: if you have access to it, levosimendan has shown promise in RV failure in some European centers. It is a calcium sensitizer with pulmonary vasodilatory effects. However, availability in India is limited and evidence remains mixed.

Just wanted to flag something from the neurocritical care angle: if this patient develops significant hemodynamic instability despite optimized vasopressors, cerebral oximetry (NIRS) monitoring can be valuable. In my neuro-ICU patients with concurrent septic shock, I have seen brain oxygenation drop before MAP drops, giving us a few minutes of advance warning.

Not directly relevant to the vasopressor sequencing question, but worth considering for monitoring.

4 Answers